The original disclosure in Japanese was released on July 29, 2015 at 15:30 (GMT+9)

Consolidated Financial Statements for the First Quarter Ended June 30, 2015
FY2016 (April 1, 2015 - March 31, 2016) [UNAUDITED]

Company name: Takara Holdings Inc.
Stock exchange listings: Tokyo Stock Exchange (1st section)
Code number: 2531
URL: http://www.takara.co.jp/
Company representative: Toshio Kakimoto, President
Contact: Takuya Kakemi, General Manager of Financial & Investor Relations Dept.
TEL : (075)241-5124

Quarterly statement filing date (as planned): August 7, 2015

Notes: 1. The accompanying financial statements have been prepared in accordance with accounting principles and practices generally accepted in Japan.
2. Amounts are rounded down to the nearest million yen.

1. Results for the three months ended June 30, 2015 (April 1, 2015 - June 30, 2015)

(1) Operating results

Note: Percentages indicated changes from the previous fiscal year.

	Three months ended June 30, 2015		Three months ended June 30, 2014	
	(Millions of yen)	(%)	(Millions of yen)	(%)
Net sales	50,938	1.8	50,025	6.5
Operating income (loss)	649	(45.1)	1,182	-
Ordinary income (loss)	1,061	(28.6)	1,486	-
Net income (loss) attributable to owners of the parent	662	(18.4)	811	-
Net income (loss) per share (Yen)	3.29		4.03	
Fully diluted net income per share (Yen)	-		-	
Note: Comprehensive income	(357)	-	149	(93.7)

(2) Financial position

	As of June 30, 2015	As of March 31, 2015
	(Millions of yen)	(Millions of yen)
Total assets	250,922	264,438
Net assets	153,924	158,404
Equity ratio (%)	51.2	49.9
(Reference) Equity	128,375	131,923

2. Dividends

	Dividend per share (Yen)		
	Year ended March 31, 2015	Year ending March 31, 2016	Year ending March 31, 2016 (Forecast)
First quarter end	-	-	
Second quarter end	-		-
Third quarter end	-		-
Year end	10.00		11.00
Annual	10.00		11.00

Note: Correction of dividend forecast from the most recent dividend forecast : No

3. Forecast for the year ending March 31, 2016 (April 1, 2015 - March 31, 2016)

Note: Percentages indicated changes from the same period of the previous fiscal year.

	Six months ending September 30, 2015		Year ending March 31, 2016	
	(Millions of yen)	(%)	(Millions of yen)	(%)
Net sales	105,500	4.3	230,000	4.8
Operating income (loss)	2,900	(11.5)	11,300	1.8
Ordinary income (loss)	3,100	(9.6)	12,000	1.5
Net income (loss) attributable to owners of the parent	1,500	(18.0)	6,400	12.2
Net income per share (Yen)	7.45		31.81	

Note: Correction of financial forecast from the most recent financial forecast : No

4. Others

(1) Material changes in subsidiaries during this period
(Changes in scope of consolidations resulting from change is subsidiaries) : No

(2) Applying of specific accounting of the consolidated quarterly financial statements : No

(3) Changes in accounting policies, accounting estimates and retrospective restatement
1) Changes based on revisions of accounting standard : Yes
2) Changes other than ones based on revisions of accounting standard : No
3) Changes in accounting estimates : No
4) Restatement : No

(4) Number of outstanding shares (common stock)
1) Number of outstanding shares at year end (Treasury stocks are included)
As of June 30, 2015 : 217,699,743
As of March 31, 2015 : 217,699,743
2) Number of treasury stocks at year end
As of June 30, 2015 : 16,474,219
As of March 31, 2015 : 16,474,061
3) Average number of outstanding shares
Three months ended June 30, 2015 : 201,225,603
Three months ended June 30, 2014 : 201,230,699

Contents of the attached document

1. Qualitative Information for the Three Months Ended June 30, 2015 ---------- 2
   (1) Consolidated Financial Results ---------- 2
   (2) Consolidated Financial Position ---------- 3
   (3) Qualitative Information Regarding Consolidated Forecasts ---------- 3
2. Summary Information (Notes)---------- 4
   Change in Accounting Policies and Changes and Retrospective Restatement of Accounting Estimates---- 4
3. Consolidated Quarterly Financial Statements ---------- 5
   (1) Consolidated Quarterly Balance Sheets ---------- 5
   (2) Consolidated Quarterly Statements of Income and Consolidated Quarterly Statements of Comprehensive Income (For the Three Months Ended June 30, 2015and 2014) ---------- 7
   Consolidated Quarterly Statements of Income (For the Three Months Ended June 30, 2015 and 2014) --- 7
   Consolidated Quarterly Statements of Comprehensive Income (For the Three Months Ended June 30, 2015 and 2014) ---------- 8
   (3) Notes on Consolidated Quarterly Financial Statements ---------- 9
   (Notes on Premise of Going Concern) ---------- 9
   (Notes on Material Changes in Shareholders' Equity) ---------- 9
   (Segment Information) ---------- 9

Supplement for the Consolidated Quarterly Financial Statements

1. Qualitative Information for the Three Months Ended June 30, 2015

(1) Consolidated Financial Results

In the three months ended June 30, 2015, the Japanese economy maintained a moderate recovery as corporate earnings, primarily among export-related companies, and the hiring and income environment improved.

On the other hand, overseas, while the American economy continued on a recovery path, there was uncertainty for the future of the global economy caused by concerns over economic slowdown in China, the Greek debt problem being faced in Europe, and other issues.

In this environment, under the Takara Group Medium-Term Management Plan FY2017, the second step in its efforts to realize its long-term Takara Group Vision 2020, the Group strived to conduct steady business activities with the aim of improving domestic business profitability and expand our overseas business intending to further increase the corporate value of the Group, while at the same time building a well-balanced business structure that can hold up well to business environment changes by accelerating the growth of our Biomedical Business.

As a result, in the three months ended June 30, 2015, net sales were up 1.8% year on year to ¥50,938 million. Gross profit rose 3.3% year on year to ¥19,615 million. Operating income declined 45.1% year on year to ¥649 million while ordinary income fell 28.6% year on year to ¥1,061 million. Net income attributable to owners of the parent fell 18.4% year on year to ¥662 million.

Results by business segment were as follows.

[Takara Shuzo Group]

For alcoholic beverages, in the three months ended June 30, 2015, sales of sake increased, as *Sho-Chiku-Bai Ten* in particular sold well, and, overseas, TAKARA SAKE USA INC. also performed strongly. Sales of light-alcohol refreshers also rose as the new *Takara Fruit Juice Zero Sugar Chu-Hi Zero Jitate* was launched in June and sales of *Takara Shochu High Ball* remained robust.

Nevertheless, sales of alcoholic beverages overall, including other alcoholic beverages, declined as shochu products recorded a fall in sales for both *ko*-type shochu and *Honkaku* shochu.

In the Seasonings Business, sales of mirin and cooking sake increased while sales of raw alcohol, etc. and transportation sales also increased.

Moreover, sales in the Japanese Food Wholesale Business in overseas markets increased as FOODEX S.A.S. (France) and COMINPORT DISTRIBUCIÓN S.L. (Spain) continued to perform strongly.

As a result, net sales for the Takara Shuzo Group fell 0.3% year on year to ¥44,231 million. Cost of sales declined 0.5% to ¥28,466 million in conjunction with the decline in net sales. As a result, gross profit rose 0.1% year on year to ¥15,764 million. SG&A expenses were up 3.1% year on year to ¥15,384 million due to an increase in advertising expenses. Accordingly, the Takara Shuzo Group recorded operating income down 54.2% year on year to ¥380 million in the three months ended June 30, 2015.

[Takara Bio Group]

Net sales for the three months ended June 30, 2015 increased 20.5% year on year to ¥5,761 million, which was due in part to the impact of the depreciation in the value of the yen in addition to sales of mainstay research reagents, which outperformed the same period of the previous fiscal year. Cost of sales was up 20.4% year on year to ¥2,439 in conjunction with the increase in net sales. Consequently, gross profit rose 20.6% year on year to ¥3,322 million. Although SG&A expenses were up 19.4% year on year to ¥3,210 million due to increases in research and development and personnel expenses, the Takara Bio Group recorded operating income up 70.8% year on year to ¥111 million in the three months ended June 30, 2015.

[Takara Healthcare]

Net sales for the three months ended June 30, 2015 increased by 24.0% year on year to ¥478 million as sales of *fucoidan*-related products and OEM cosmetics continued to grow. Cost of sales was up 28.2% year on year to ¥241 million in conjunction with the increase in net sales. Consequently, gross profit increased 20.0% year on year to ¥236 million. SG&A expenses were up 24.6% year on year to ¥234 million, mainly due to the increase in advertising expenses. As a result, Takara Healthcare recorded operating income down by 73.3% year on year to ¥2 million.

[Other]

Net sales of business segments other than the reported segments decreased 4.2% year on year to ¥1,286 million. Cost of sales fell 3.0% year on year to ¥1,138 million. Consequently, gross profit fell 12.6% year on year to ¥148 million. SG&A expenses were down 2.0% year on year to ¥169 million. As a result, a ¥20 million operating loss was recorded, compared to a ¥2 million operating loss recorded in the same period of the previous fiscal year.

Breakdown of sales results by product category

Segment	Equivalent Period of Previous Fiscal Year (From April 1, 2014, to June 30, 2014)	Period under Review (from April 1, 2015, to June 30, 2015)	YoY Comparison
Product category	Amount (Millions of yen)	Amount (Millions of yen)	(%)
Takara Shuzo Group			
Shochu	16,609	14,323	86.2
Sake	4,238	4,503	106.3
Light-alcohol refreshers	6,403	6,876	107.4
Other alcoholic beverages	3,239	3,173	98.0
Alcoholic beverages total	30,491	28,877	94.7
Hon Mirin	3,097	3,332	107.6
Other seasonings	2,014	2,103	104.4
Seasonings total	5,111	5,435	106.3
Raw alcohol, etc.	1,588	1,902	119.8
Transportation	2,731	3,012	110.3
Japanese Food Wholesales Business in overseas markets	4,032	4,646	115.2
Other	415	357	86.1
Total	44,370	44,231	99.7
Takara Bio Group	4,779	5,761	120.5
Takara Healthcare	385	478	124.0
Other	1,342	1,286	95.8
Sales not allocated to business segments and intersegment transactions	(852)	(818)	-
Total	**50,025**	**50,938**	**101.8**

Notes: 1. Amounts include alcohol tax but do not include consumption tax.
2. From the first quarter of this fiscal year, the Company has made changes to reporting segments, and sales results for the first quarter of the previous fiscal year have been prepared and presented in accordance with the reporting segments following the changes.
See "(3) Notes on Consolidated Quarterly Financial Statements (Segment Information)" for details of changes to reporting segments.

(2) Consolidated Financial Position

Total assets stood at ¥250,922 million as of June 30, 2015, down ¥13,516 million from March 31, 2015. This was due to a ¥13,016 million decrease in current assets from the end of the previous fiscal year to ¥147,636 million. This primarily resulted from a decline of ¥11,441 million in securities and a decline of ¥3,394 million in notes and accounts receivable-trade.

Non-current assets decreased by ¥500 million from the end of the previous fiscal year to ¥103,285 million. The main factors were decreases of ¥852 million in property, plant and equipment and ¥948 million in intangible assets, and an increase of ¥1,489 million in investment securities.

Total liabilities amounted to ¥96,997 million as of June 30, 2015, down ¥9,036 million from March 31, 2015. Current liabilities fell ¥9,030 million from the end of the previous fiscal year to ¥45,847 million. This primarily resulted from a decline of ¥5,000 million in the current portion of bonds and a decline of ¥1,732 million in notes and accounts payable-trade.

Non-current liabilities declined ¥6 million from the end of the previous fiscal year to ¥51,150 million.

Net assets stood at ¥153,924 million as of June 30, 2015, down ¥4,479 million from March 31, 2015. The main factors were a decrease of ¥1,316 million in capital surplus, a decrease of ¥1,349 million in retained earnings due to ¥662 million in net income attributable to owners of the parent and ¥2,012 million in dividends from surplus, and a ¥1,827 million decrease in foreign currency translation adjustment.

(3) Qualitative Information Regarding Consolidated Forecasts

The consolidated performance for the three months ended June 30, 2015 exceeded initial forecasts. Nevertheless, the Company has not revised the consolidated forecasts for the six months ending September 30, 2015 or for the fiscal year ending March 31, 2016 that were released on May 8, 2015 because the proportion of the Group's annual income accounted for by income in the first quarter of the fiscal year is relatively low.

2. Summary Information (Notes)

Change in Accounting Policy and Retrospective Restatement of Accounting Estimates

(Change in Accounting Policy)

(Application of Revised Accounting Standard for Business Combinations, etc.)

The "Revised Accounting Standard for Business Combinations (ASBJ Statement No. 21, September 13, 2013, hereinafter the "Business Combinations Accounting Standard"), the "Revised Accounting Standard for Consolidated Financial Statements (ASBJ Statement No. 22, September 13, 2013, hereinafter the "Consolidated Financial Statements Accounting Standard"), and the "Revised Accounting Standard for Business Divestitures" (ASBJ Statement No. 7, September 13, 2013, hereinafter the "Business Divestitures Accounting Standard") have been applied from the first quarter of this fiscal year. As a result, for subsidiaries the Company continues to control, differences arising due to changes in the ownership interest are entered in capital surplus and costs associated with the acquisition of ownership interests are now treated as expenses in the consolidated fiscal year in which they are incurred. In addition, for business combinations that are implemented after the beginning of the first quarter of 2015, revisions to the allocation of the cost of acquisitions as determined by provisional accounting treatment are reflected in the quarterly consolidated financial statements for the quarter in which the business combination took place. Additionally, the Company has changed the method of presenting consolidated quarterly net income and changed "minority interests in consolidated subsidiaries" to "non-controlling interests in consolidated subsidiaries." To reflect these changes, the Company has reclassified its quarterly consolidated financial statements for the first quarter of the previous fiscal year and consolidated financial statements for the previous fiscal year.

The Company has applied these standards in accordance with the transitional treatment prescribed in Section 58-2 (4) of the Business Combinations Accounting Standard, Section 44-5 (4) of the Consolidated Financial Statements Accounting Standard, and Section 57-4 (4) of the Business Divestitures Accounting Standard, and will continue to apply these standards from the beginning of the first quarter of this fiscal year into the future.

As a result of these changes, operating income, ordinary income, and net income before taxes declined by ¥4 million respectively. Capital surplus also declined by ¥1,316 million as of June 30, 2015, the end of the first quarter of this fiscal year.

3. Consolidated Quarterly Financial Statements

(1) Consolidated Quarterly Balance Sheets

(Millions of Yen)

	As of Mar. 31, 2015	As of June. 30, 2015
Assets		
Current assets		
Cash and deposits	41,296	40,836
Notes and accounts receivable-trade	54,617	51,223
Securities	27,022	15,581
Merchandise and finished goods	28,524	29,440
Work in process	958	1,082
Raw materials and supplies	3,317	3,093
Other	5,148	6,587
Allowance for doubtful accounts	(233)	(207)
Total current assets	160,653	147,636
Noncurrent assets		
Property, plant and equipment	53,085	52,232
Intangible assets		
Goodwill	8,071	7,319
Other	4,286	4,090
Total intangible assets	12,358	11,410
Investments and other assets		
Investment securities	32,900	34,389
Other	5,608	5,419
Allowance for doubtful accounts	(166)	(166)
Total investments and other assets	38,342	39,642
Total noncurrent assets	103,785	103,285
Total assets	264,438	250,922

(Millions of Yen)

	As of Mar. 31, 2015	As of June. 30, 2015
Liabilities		
Current liabilities		
Notes and accounts payable-trade	15,680	13,948
Short-term loans payable	5,292	5,364
Current portion of bonds	5,000	-
Accrued alcohol tax	7,615	7,838
Accrued expenses	5,456	4,312
Income taxes payable	2,107	986
Provision for bonuses	2,162	3,363
Other provision	1,868	2,036
Other	9,695	7,996
Total current liabilities	54,877	45,847
Noncurrent liabilities		
Bonds payable	20,000	20,000
Long-term loans payable	10,334	10,348
Net defined benefit liability	8,407	8,465
Long-term deposits received	5,622	5,528
Other	6,792	6,808
Total noncurrent liabilities	51,156	51,150
Total liabilities	106,034	96,997
Net assets		
Shareholders' equity		
Capital stock	13,226	13,226
Capital surplus	3,196	1,879
Retained earnings	108,647	107,297
Treasury stock	(9,937)	(9,937)
Total shareholders' equity	115,132	112,465
Accumulated other comprehensive income		
Valuation difference on available-for-sale securities	9,098	10,091
Deferred gains or losses on hedges	558	526
Foreign currency translation adjustment	7,431	5,603
Remeasurements of defined benefit plans	(297)	(311)
Total accumulated other comprehensive income	16,791	15,909
Noncontrolling interests	26,481	25,549
Total net assets	158,404	153,924
Total liabilities and net assets	264,438	250,922

(2) Consolidated Quarterly Statements of Income and Consolidated Quarterly Statements of Comprehensive Income

(Consolidated Statements of Income)
(For the Three Months Ended June 30, 2015 and 2014)

(Millions of Yen)

	FY2015 (Apr. 1, 2014 – June. 30, 2014)	FY2016 (Apr. 1, 2015 – June. 30, 2015)
Net sales	50,025	50,938
Cost of sales	31,031	31,323
Gross profit	18,994	19,615
Selling, general and administrative expenses	17,811	18,966
Operating income	1,182	649
Non-operating income		
Dividends income	221	231
Other	249	337
Total non-operating income	470	569
Non-operating expenses		
Interest expenses	121	115
Other	46	41
Total non-operating expenses	167	156
Ordinary income	1,486	1,061
Extraordinary income		
Gain on sales of investment securities	-	260
Other	4	4
Total extraordinary income	4	264
Extraordinary loss		
Loss on valuation of investment securities	-	23
Loss on sales and retirement of noncurrent assets	37	12
Directors' retirement benefits	34	-
Other	7	-
Total extraordinary losses	79	36
Income before income taxes and minority interests	1,411	1,289
Income taxes-current	920	1,224
Income taxes-deferred	(395)	(667)
Total income taxes	524	556
Net income	886	732
Net income attributable to the noncontrolling interest	75	70
Net income attributable to owners of the parent	811	662

(Consolidated Quarterly Statements of Comprehensive Income)
(For the Three Months Ended June 30, 2015 and 2014)

(Millions of Yen)

	FY2015 (Apr. 1, 2014 – June. 30, 2014)	FY2016 (Apr. 1, 2015 – June. 30, 2015)
Net income	886	732
Other comprehensive income		
Valuation difference on available-for-sale securities	637	992
Deferred gains or losses on hedges	(94)	(32)
Foreign currency translation adjustment	(1,181)	(2,032)
Remeasurements of defined benefit plans	(46)	(12)
Share of other comprehensive income of associates accounted for using equity method	(51)	(4)
Total other comprehensive income	(737)	(1,090)
Comprehensive income	149	(357)
(Comprehensive income attributable to)		
Comprehensive income attributable to owners of the parent	361	(219)
Comprehensive income attributable to noncontrolling interest	(212)	(138)

(3) Notes on Consolidated Quarterly Financial Statements

(Notes on Premise of Going Concern)

No items to report.

(Notes on Material Changes in Shareholders' Equity)

No items to report.

(Segment Information)

I. Equivalent Period of Previous Fiscal Year (From April 1, 2014, to June 30, 2014)

1. Net sales and Income (Loss) by Reported Segment

<Information for the first quarter of the previous fiscal year prepared in accordance with classifications following changes>

(Millions of yen)

	Reported Segment				Other (Note: 1)	Total	Adjustment (Note: 2)	Amount recognized in consolidated quarterly statements of income (Note: 3)
	Takara Shuzo Group	Takara Bio Group	Takara Healthcare	Subtotal				
Net sales								
External customers	44,287	4,635	385	49,308	605	49,913	111	50,025
Intersegment	82	143	0	226	737	963	(963)	-
Total	44,370	4,779	385	49,535	1,342	50,877	(852)	50,025
Segment income (loss)	830	65	9	905	(2)	902	280	1,182

Notes: 1. Other includes business segments that are not part of reported segments, such as the printing business and other subsidiaries.

2. Details of adjustment amounts are as follows.

(1) Net sales to external customers are income from real estate rent recognized by the Company.

(2) Segment income (loss) comprises intersegment eliminations of ¥65 million and income of the Company not allocated to business segments of ¥215 million.

3. Segment income (loss) has been adjusted to the operating income of consolidated quarterly statements of income.

2. Information on Impairment Loss on Non-current Assets, Goodwill, etc. by Reportable Segment

No items to report.

II. Period under Review (From April 1, 2015, to June 30, 2015)

1. Net sales and Income (Loss) by Reported Segment

(Millions of yen)

	Reported Segment				Other (Note: 1)	Total	Adjustment (Note: 2)	Amount recognized in consolidated quarterly statements of income (Note: 3)
	Takara Shuzo Group	Takara Bio Group	Takara Healthcare	Subtotal				
Net sales								
External customers	44,170	5,565	477	50,212	610	50,823	115	50,938
Intersegment	61	196	0	258	675	934	(934)	-
Total	44,231	5,761	478	50,471	1,286	51,757	(818)	50,938
Segment income	380	111	2	494	(20)	473	175	649

Notes: 1. Other includes business segments that are not part of reported segments, such as the printing business and other subsidiaries.

2. Details of adjustment amounts are as follows.

(1) Net sales to external customers are income from real estate rent recognized by the Company.

(2) Segment income comprises intersegment eliminations of ¥55 million and income of the Company not allocated to business segments of ¥119 million.

3. Segment income has been adjusted to the operating loss of consolidated quarterly statements of income.

2. Matters concerning Changes to Reporting Segments

(Changes to Classifications for Reporting Segments)

The Company implemented an absorption-type merger for consolidated subsidiary TaKaRa Network System Co., Ltd. on April 1, 2015. With the merger, the business of TaKaRa Network System, which was included in Other until the previous fiscal year, has been included in Adjustment from the first quarter of this fiscal year.

"Net sales and Income (Loss) by Reported Segment" for the first quarter of the previous fiscal year is presented with amounts reclassified following the relevant changes.

(Application of Revised Accounting Standard for Business Combinations, etc.)

As stated in "Change in Accounting Policy," the "Revised Accounting Standard for Business Combinations" and other standards have been applied from the first quarter of this fiscal year. As a result, for subsidiaries the Company continues to control, differences arising due to changes in the ownership interest are entered in capital surplus and costs associated with the acquisition of ownership interests are now treated as expenses in the consolidated fiscal year in which they are incurred. In addition, for business combinations that are implemented after the beginning of the first quarter of 2015, revisions to the allocation of the cost of acquisitions as determined by provisional accounting treatment are reflected in the quarterly consolidated financial statements for the quarter in which the business combination took place.

As a result of these changes, segment income for the first quarter of this fiscal year decreased by ¥4 million for the Takara Shuzo Group as compared with the previous accounting method.

3. Information on Impairment Loss on Non-current Assets, Goodwill, etc. by Reportable Segment

No items to report.

平成28年3月期
第1四半期決算短信 補足資料

Supplement for the Consolidated Financial Statements
for the First Quarter Ended June 30, 2015

1. 宝ホールディングス(連結)
   Takara Holdings Inc. -Consolidated-
   グループ別要約損益計算書
   Consolidated Statements of Income by Business Group (Summary)

2. 宝酒造グループ
   Takara Shuzo Group
   要約損益計算書
   Statements of Income (Summary)

3. タカラバイオグループ
   Takara Bio Group
   要約損益計算書
   Statements of Income (Summary)

4. 6年間の財務サマリー(グループ別)
   Six-Year Financial Summary by Business Group

宝ホールディングス株式会社
TAKARA HOLDINGS INC.

財務・IR部 Financial & Investor Relations Dept.
TEL 075(241)5124
FAX 075(241)5194
E-Mail ir@takara.co.jp

将来見通しに関する注意事項

この資料中の当社および当社グループの現在の計画、見通し、戦略、確信などのうち、歴史的事実でないものは、将来の業績に関する見通しであり、これらは現時点において入手可能な情報から得られた当社経営陣の判断に基づくものですが、重大なリスクや不確実性を含んでいる情報から得られた多くの仮定および考えに基づきなされたものであります。実際の業績は、さまざまな要素によりこれら予測とは大きく異なる結果となり得ることをご承知おきください。

実際の業績に影響を与える要素には、経済情勢、特に消費動向、為替レートの変動、法律・行政制度の変化、競合会社の価格・製品戦略による圧力、当社の既存製品および新製品の販売力の低下、生産中断、当社の知的所有権に対する侵害、急速な技術革新、重大な訴訟における不利な判決等がありますが、業績に影響を与える要素はこれらに限定されるものではありません。

Forward-Looking Statements

Statements in this document, other than those based on historical fact, concerning the current plans, prospects, strategies and expectations of the Company and its Group represent forecasts of future results. While such statements are based on the conclusions of management according to information available at the time of writing, they reflect many assumptions and opinions derived from information that includes major risks and uncertainties. Actual results may vary significantly from these forecasts due to various factors.

Factors that could influence actual results include, but are not limited to, economic conditions, especially trends in consumer spending, as well as exchange rate fluctuations, changes in laws and government systems, pressure from competitors' prices and product strategies, declines in selling power of the Company's existing and new products, disruptions to production, violations of the Company's intellectual property rights, rapid advances in technology and unfavorable verdicts in major litigation.

宝ホールディングス株式会社　財務・IR部
Takara Holdings Inc. Financial & Investor Relations Dept.

TEL 075(241)5124　FAX 075(241)5194
E-Mail ir@takara.co.jp

1. 宝ホールディングス(連結) :Takara Holdings Inc. -Consolidated-

グループ別要約損益計算書 :Consolidated Statements of Income by Business Group (Summary)

(百万円 :Millions of Yen)

	平成27年3月期 第1四半期	平成28年3月期 第1四半期 Apr. 1, 2015 - Jun. 30, 2015		
	実績(a) FY2015 (1stQ) Actual (a)	実績(b) FY2016 (1stQ) Actual (b)	増減(b-a) Change (b-a)	比(b/a) YOY% (b/a)
宝酒造 グループ Takara Shuzo Group	44,370	44,231	△ 138	99.7%
タカラバイオ グループ Takara Bio Group	4,779	5,761	982	120.5%
宝ヘルスケア Takara Healthcare Inc.	385	478	92	124.0%
その他 Other, net	490	467	△ 22	95.3%
売上高 Net sales	50,025	50,938	913	101.8%
売上原価 Cost of sales	31,031	31,323	291	100.9%
売上総利益 Gross profit	18,994	19,615	621	103.3%
運送費、保管料 Transportation and storage	1,900	1,974	74	103.9%
広告宣伝費 Advertising	706	952	246	134.9%
販売促進費、販売促進引当金繰入 Sales promotion and allowance for s.p.	8,198	8,169	△ 28	99.7%
研究開発費 Research and development	792	1,103	311	139.3%
管理費、その他 Other, net	6,214	6,765	551	108.9%
販売費及び一般管理費 SG&A expenses	17,811	18,966	1,155	106.5%
宝酒造 グループ Takara Shuzo Group	830	380	△ 450	45.8%
タカラバイオ グループ Takara Bio Group	65	111	46	170.8%
宝ヘルスケア Takara Healthcare Inc.	9	2	△ 6	26.7%
その他 Other, net	277	155	△ 122	55.9%
営業利益(△:損失) Operating income(Δ:loss)	1,182	649	△ 533	54.9%
受取利息・配当金 Interest and Dividends income	267	292	25	109.5%
その他営業外収益 Other, net	203	276	72	135.8%
営業外収益 Non-operating income	470	569	98	120.8%
支払利息 Interest and discounts expenses	121	115	△ 6	94.8%
その他営業外費用 Other, net	46	41	△ 4	90.4%
営業外費用 Non-operating expenses	167	156	△ 10	93.6%
経常利益(△:損失) Ordinary income(Δ:loss)	1,486	1,061	△ 424	71.4%
特別利益 Extraordinary gain	4	264	259	5296.7%
特別損失 Extraordinary loss	79	36	△ 43	45.6%
税金等調整前四半期純利益(△:損失) Income(Δ:loss) before income taxes	1,411	1,289	△ 121	91.4%
法人税、住民税及び事業税 Current income taxes 法人税等調整額 Deferred income taxes	524	556	32	106.2%
四半期純利益(△:損失) Net income(Δ:loss)	886	732	△ 154	82.6%
非支配株主に帰属する四半期純利益(△:損失) Net income attributable to the noncontrolling interest(Δ:loss)	75	70	△ 4	93.7%
親会社株主に帰属する四半期純利益(△:損失) Net income attributable to owners of the parent(Δ:loss)	811	662	△ 149	81.6%
設備投資額(有形・無形) Capital expenditures	2,012	365	△ 1,646	18.2%
減価償却費(有形・無形) Depreciation and Amortization	1,012	1,216	204	120.2%
のれん償却額 Amortization of goodwill	116	133	16	114.2%

営業外収益 Non-operating income	受取利息60、受取配当金231、持分法による投資利益100、生命保険配当金68、補助金収入34 など Interest income 60, Dividends income 231, Equity in earnings of affiliates 100, Dividend income of life insurance 68 、Subsidy income 34 etc.
営業外費用 Non-operating expenses	支払利息46、社債利息68 など Interest expenses 46, Interest on bonds 68, etc.
特別利益 Extraordinary gain	投資有価証券売却益260 など Gain on sales of investment securities 260, etc.
特別損失 Extraordinary loss	投資有価証券評価損23 など (前期:役員退職慰労金34 など) Loss on valuation of investment securities 23, etc. (FY2015(1Q): Directors' retirement benefits 34, etc.)

2. 宝酒造グループ :Takara Shuzo Group

要約損益計算書 :Statements of Income (Summary)

（百万円 :Millions of Yen）

	平成27年3月期 第1四半期	平成28年3月期 第1四半期 Apr. 1, 2015 - Jun. 30, 2015		
	実績(a) FY2015 (1stQ) Actual (a)	実績(b) FY2016 (1stQ) Actual (b)	増減(b−a) Change (b-a)	比(b/a) YOY% (b/a)
焼酎 Shochu	16,609	14,323	△ 2,286	86.2%
清酒 Sake	4,238	4,503	265	106.3%
ソフトアルコール飲料 Light-alcohol refreshers	6,403	6,876	472	107.4%
その他酒類 Other liquors	3,239	3,173	△ 66	98.0%
本みりん Hon Mirin	3,097	3,332	234	107.6%
その他調味料 Other seasonings	2,014	2,103	89	104.4%
原料用アルコール等 Raw alcohol	1,588	1,902	314	119.8%
海外日本食材卸 Japanese food wholesale business in overseas markets	4,032	4,646	613	115.2%
その他 Other	3,146	3,370	223	107.1%
売上高 Net sales	44,370	44,231	△ 138	99.7%
売上原価 Cost of sales	28,623	28,466	△ 156	99.5%
売上総利益 Gross profit	15,746	15,764	18	100.1%
運送費、保管料 Transportation and storage	1,726	1,796	69	104.0%
広告宣伝費 Advertising	599	817	217	136.2%
販売促進費、販売促進引当金繰入 Sales promotion and allowance for s.p.	7,970	7,927	△ 42	99.5%
研究開発費 Research and development	84	81	△ 2	96.6%
管理費、その他 Other, net	4,534	4,761	226	105.0%
販売費及び一般管理費 SG&A expenses	14,916	15,384	468	103.1%
営業利益（△：損失） Operating income(Δ:loss)	830	380	△ 450	45.8%
営業外収益 Non-operating income	193	255	62	132.1%
営業外費用 Non-operating expenses	92	104	11	112.4%
経常利益（△：損失） Ordinary income(Δ:loss)	931	531	△ 399	57.1%
特別利益 Extraordinary gain	4	3	△ 1	79.0%
特別損失 Extraordinary loss	67	29	△ 37	44.3%
税金等調整前四半期純利益（△：損失） Income(Δ:loss) before income taxes	869	505	△ 363	58.2%
法人税、住民税及び事業税 Current income taxes	323	156	△ 166	48.5%
法人税等調整額 Deferred income taxes				
四半期純利益（△：損失） Net income(Δ:loss)	545	349	△ 196	64.0%
非支配株主に帰属する四半期純利益（△：損失） Net income attributable to the noncontrolling interest(Δ:loss)	61	70	9	114.9%
親会社株主に帰属する四半期純利益（△：損失） Net income attributable to owners of the parent(Δ:loss)	484	278	△ 205	57.5%

設備投資額（有形・無形） Capital expenditures	1,206	273	△ 933	22.7%
減価償却費（有形・無形） Depreciation and Amortization	705	765	59	108.4%
のれん償却額 Amortization of goodwill	85	88	2	103.2%

3. タカラバイオグループ :Takara Bio Group

要約損益計算書 :Statements of Income (Summary)

（百万円 :Millions of Yen）

	平成27年3月期 第1四半期	平成28年3月期 第1四半期 Apr. 1, 2015 - Jun. 30, 2015		
	実績(a) FY2015 (1stQ) Actual (a)	実績(b) FY2016 (1stQ) Actual (b)	増減(b−a) Change (b-a)	比(b/a) YOY% (b/a)
研究用試薬 Research reagents	3,562	4,277	714	120.1%
理化学機器 Scientific instruments	293	415	121	141.6%
受託・その他ファイン Contracted service and other	487	611	124	125.6%
バイオ産業支援　計 Bioindustry	4,342	5,304	961	122.1%
遺伝子医療 Gene therapy	—	—	—	—
医食品バイオ AgriBio	436	457	20	104.7%
売上高 Net sales	4,779	5,761	982	120.5%
売上原価 Cost of sales	2,024	2,439	414	120.4%
売上総利益 Gross profit	2,754	3,322	567	120.6%
運送費、保管料 Transportation and storage	146	148	2	101.9%
広告宣伝費 Advertising	28	24	△ 4	83.8%
販売促進費 Sales promotion	204	215	11	105.6%
研究開発費 Research and development	703	1,020	316	145.0%
管理費、その他 Other, net	1,605	1,801	195	112.2%
販売費及び一般管理費 SG&A expenses	2,689	3,210	521	119.4%
バイオ産業支援　計 Bioindustry	798	991	192	124.1%
遺伝子医療 Gene therapy	△ 211	△ 420	△ 208	—
医食品バイオ AgriBio	△ 149	△ 46	103	—
共通 Eliminations/Corporate	△ 372	△ 413	△ 41	—
営業利益（△：損失） Operating income(Δ:loss)	65	111	46	170.8%
営業外収益 Non-operating income	55	108	53	197.1%
営業外費用 Non-operating expenses	18	2	△ 15	15.3%
経常利益（△：損失） Ordinary income(Δ:loss)	102	217	115	212.7%
特別利益 Extraordinary gain	—	0	0	—
特別損失 Extraordinary loss	10	6	△ 4	60.2%
税金等調整前四半期純利益（△：損失） Income(Δ:loss) before income taxes	91	211	119	231.1%
法人税、住民税及び事業税 Current income taxes	75	245	170	326.4%
法人税等調整額 Deferred income taxes				
四半期純利益（△：損失） Net income(Δ:loss)	16	△ 33	△ 50	—
非支配株主に帰属する四半期純利益（△：損失） Net income attributable to the noncontrolling interest(Δ:loss)	△ 2	2	4	—
親会社株主に帰属する四半期純利益（△：損失） Net income attributable to owners of the parent(Δ:loss)	18	△ 36	△ 55	—

設備投資額（有形・無形） Capital expenditures	782	90	△ 691	11.6%
減価償却費（有形・無形） Depreciation and Amortization	269	392	123	145.8%
のれん償却額 Amortization of goodwill	30	44	13	144.6%

4. 6年間の財務サマリー（グループ別） :Six-Year Financial Summary by Business Group

宝ホールディングス（連結） :Takara Holdings Inc. -Consolidated-

（百万円 :Millions of Yen）

		平成23年3月期 第1四半期 FY2011 (1stQ)	平成24年3月期 第1四半期 FY2012 (1stQ)	平成25年3月期 第1四半期 FY2013 (1stQ)	平成26年3月期 第1四半期 FY2014 (1stQ)	平成27年3月期 第1四半期 FY2015 (1stQ)	平成28年3月期 第1四半期 FY2016 (1stQ)	前期対比 Change from FY2015(1stQ) 増減 Change	前期対比 Change from FY2015(1stQ) 比 YOY%
売上高	Net sales	44,554	48,866	47,349	46,953	50,025	50,938	913	101.8%
売上原価	Cost of sales	27,234	30,007	29,075	29,570	31,031	31,323	291	100.9%
（売上高原価率）	(Ratio to Net sales)	61.1%	61.4%	61.4%	63.0%	62.0%	61.5%	-0.5pt	—
売上総利益	Gross profit	17,319	18,859	18,273	17,382	18,994	19,615	621	103.3%
販売費及び一般管理費	SG&A expenses	16,207	17,194	17,212	17,624	17,811	18,966	1,155	106.5%
（売上高販管費率）	(Ratio to Net sales)	36.4%	35.2%	36.4%	37.5%	35.6%	37.2%	+1.6pt	—
営業利益（△：損失）	Operating income(Δ:loss)	1,111	1,664	1,061	Δ 241	1,182	649	Δ 533	54.9%
（売上高営業利益率）	(Ratio to Net Sales)	2.5%	3.4%	2.2%	—	2.4%	1.3%	-1.1pt	—
販売促進費、販売促進引当金繰入	Sales promotion and allowance for s.p.	7,590	7,909	8,170	8,221	8,198	8,169	Δ 28	99.7%
（売上高販促費率）	(Ratio to Net sales)	17.0%	16.2%	17.3%	17.5%	16.4%	16.0%	-0.3pt	—
研究開発費	R&D expenses	685	701	737	792	792	1,103	311	139.3%
（売上高研究開発費率）	(Ratio to Net sales)	1.5%	1.4%	1.6%	1.7%	1.6%	2.2%	+0.6pt	—
設備投資額（有形・無形）	Capital expenditures	532	638	998	1,777	2,012	365	Δ 1,646	18.2%
減価償却費（有形・無形）	Depreciation and Amortization	1,081	1,061	999	996	1,012	1,216	204	120.2%
のれん償却額	Amortization of goodwill	31	69	68	75	116	133	16	114.2%

宝酒造グループ :Takara Shuzo Group

（百万円 :Millions of Yen）

		平成23年3月期 第1四半期 FY2011 (1stQ)	平成24年3月期 第1四半期 FY2012 (1stQ)	平成25年3月期 第1四半期 FY2013 (1stQ)	平成26年3月期 第1四半期 FY2014 (1stQ)	平成27年3月期 第1四半期 FY2015 (1stQ)	平成28年3月期 第1四半期 FY2016 (1stQ)	前期対比 Change from FY2015(1stQ) 増減 Change	前期対比 Change from FY2015(1stQ) 比 YOY%
売上高	Net sales	39,728	44,118	42,291	41,978	44,370	44,231	Δ 138	99.7%
売上原価	Cost of sales	25,026	27,839	27,025	27,242	28,623	28,466	Δ 156	99.5%
（売上高原価率）	(Ratio to Net sales)	63.0%	63.1%	63.9%	64.9%	64.5%	64.4%	-0.2pt	—
売上総利益	Gross profit	14,702	16,278	15,266	14,735	15,746	15,764	18	100.1%
販売費及び一般管理費	SG&A expenses	13,727	14,781	14,680	14,869	14,916	15,384	468	103.1%
（売上高販管費率）	(Ratio to Net sales)	34.6%	33.5%	34.7%	35.4%	33.6%	34.8%	+1.2pt	—
営業利益（△：損失）	Operating income(Δ:loss)	974	1,496	585	Δ 134	830	380	Δ 450	45.8%
（売上高営業利益率）	(Ratio to Net sales)	2.5%	3.4%	1.4%	—	1.9%	0.9%	-1.0pt	—
販売促進費、販売促進引当金繰入	Sales promotion and allowance for s.p.	7,356	7,694	7,942	7,977	7,970	7,927	Δ 42	99.5%
（売上高販促費率）	(Ratio to Net sales)	18.5%	17.4%	18.8%	19.0%	18.0%	17.9%	-0.0pt	—
設備投資額（有形・無形）	Capital expenditures	265	386	331	369	1,206	273	Δ 933	22.7%
減価償却費（有形・無形）	Depreciation and Amortization	765	763	703	683	705	765	59	108.4%
のれん償却額	Amortization of goodwill	—	37	37	43	85	88	2	103.2%

タカラバイオグループ :Takara Bio Group

（百万円 :Millions of Yen）

		平成23年3月期 第1四半期 FY2011 (1stQ)	平成24年3月期 第1四半期 FY2012 (1stQ)	平成25年3月期 第1四半期 FY2013 (1stQ)	平成26年3月期 第1四半期 FY2014 (1stQ)	平成27年3月期 第1四半期 FY2015 (1stQ)	平成28年3月期 第1四半期 FY2016 (1stQ)	前期対比 Change from FY2015(1stQ) 増減 Change	前期対比 Change from FY2015(1stQ) 比 YOY%
売上高	Net sales	3,772	3,823	4,104	4,170	4,779	5,761	982	120.5%
売上原価	Cost of sales	1,607	1,683	1,569	1,977	2,024	2,439	414	120.4%
（売上高原価率）	(Ratio to Net sales)	42.6%	44.0%	38.2%	47.4%	42.4%	42.3%	-0.0pt	—
売上総利益	Gross profit	2,164	2,140	2,535	2,192	2,754	3,322	567	120.6%
販売費及び一般管理費	SG&A expenses	2,197	2,188	2,360	2,551	2,689	3,210	521	119.4%
（売上高販管費率）	(Ratio to Net sales)	58.3%	57.2%	57.5%	61.2%	56.3%	55.7%	-0.5pt	—
営業利益（△：損失）	Operating income(Δ:loss)	Δ 32	Δ 48	175	Δ 358	65	111	46	170.8%
（売上高営業利益率）	(Ratio to Net sales)	—	—	4.3%	—	1.4%	1.9%	+0.6pt	—
研究開発費	R&D expenses	595	608	646	704	703	1,020	316	145.0%
（売上高研究開発費率）	(Ratio to Net sales)	15.8%	15.9%	15.7%	16.9%	14.7%	17.7%	+3.0pt	—
設備投資額（有形・無形）	Capital expenditures	227	238	475	1,390	782	90	Δ 691	11.6%
減価償却費（有形・無形）	Depreciation and Amortization	280	263	263	271	269	392	123	145.8%
のれん償却額	Amortization of goodwill	35	31	31	32	30	44	13	144.6%

宝ヘルスケア :Takara Healthcare Inc.

（百万円 :Millions of Yen）

		平成23年3月期 第1四半期 FY2011 (1stQ)	平成24年3月期 第1四半期 FY2012 (1stQ)	平成25年3月期 第1四半期 FY2013 (1stQ)	平成26年3月期 第1四半期 FY2014 (1stQ)	平成27年3月期 第1四半期 FY2015 (1stQ)	平成28年3月期 第1四半期 FY2016 (1stQ)	前期対比 Change from FY2015(1stQ) 増減 Change	前期対比 Change from FY2015(1stQ) 比 YOY%
売上高	Net sales	693	615	551	292	385	478	92	124.0%
売上原価	Cost of sales	493	406	355	133	188	241	53	128.2%
（売上高原価率）	(Ratio to Net sales)	71.1%	66.0%	64.5%	45.6%	48.8%	50.5%	+1.7pt	—
売上総利益	Gross profit	200	209	195	159	197	236	39	120.0%
販売費及び一般管理費	SG&A expenses	272	252	203	198	188	234	46	124.6%
（売上高販管費率）	(Ratio to Net sales)	39.3%	41.1%	36.8%	67.9%	48.8%	49.0%	+0.2pt	—
営業利益（△：損失）	Operating income(Δ:loss)	Δ 72	Δ 43	Δ 7	Δ 39	9	2	Δ 6	26.7%
（売上高営業利益率）	(Ratio to Net sales)	—	—	—	—	2.4%	0.5%	-1.9pt	—
ヘルスケア事業売上高	Net sales of Healthcare products	265	264	314	292	385	478	92	124.0%
設備投資額（有形・無形）	Capital expenditures	—	3	—	1	—	1	1	—
減価償却費（有形・無形）	Depreciation and Amortization	2	2	2	0	0	0	0	274.2%